Phil Mallinder

Executive Director Head Early Oncology Project Management @AstraZeneca

Cambridge, GB
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Nov 2022 — Present

Executive Director Head Early Oncology Project Management @AstraZeneca

View department →

Cambridge, GB

Group Leader of ~30 Global Project Managers that manage the AstraZeneca early oncology portfolio from pre-Candidate Drug to Phase 3 Investment Decision.

EDUCATION

1983 — 1990

The University of Sheffield

BSc PhD, Biochemistry, Microbiology

SKILLS

Translational ScienceDrug DiscoveryMonoclonal AntibodiesRespiratory DiseaseAssay DevelopmentInflammationAsthmaResearch Project ManagementIn VivoDrug DesignMolecular BiologyProject Portfolio ManagementProject ManagementClinical DevelopmentOncologyBuilding RelationshipsValidationTarget ValidationContract ResearchCopdTranslational ResearchBiotechnologyDrug DevelopmentPharmacologyBiomarkersCROIn Vitro

ABOUT PHIL MALLINDER

I am Group Leader of AstraZeneca early oncology Global Project Management. My team of ~30 project managers manage the AstraZeneca early oncology portfolio of diverse drug development projects spanning from pre-CD nomination to proof of concept. The AstraZeneca early portfolio has multiple drug modalities including small molecules, PROTACs, T-Cell Engagers, Antibody Drug Conjugates and Cell Therapies. I have over 30 years experience in pharma and biotech industries. In the past I’ve been leader of multiple antibody and low molecular weight drug discovery multidisciplinary* teams that delivered 10 candidate drugs through key milestones into early development.I’ve led or managed projects targeting the diseases: cancer/oncology (NSCLC, Prostate, CRC, HNSCC, Pancreatic, Cervical, ovarian) asthma, inflammation, COPD, pulmonary arterial hypertension (PAH), rheumatoid arthritis and inflammatory bowel disease.*Cross functional teams included experts in; biochemistry, pharmacology, crystallography, in vivo models, biomarkers, translational science, medicinal chemistry, computational chemistry, fragment screening, structure-based drug design, lead optimisation, drug metabolism and pharmacokinetics (DMPK), ADME, drug-protein interactions, toxicology, process chemistry, CMC, formulation, pharmacy, intellectual property, regulatory affairs, toxicology, clinical development and clinical operations.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Phil Mallinder — Executive Director Head Early Oncology Project Management at AstraZeneca in Cambridge, GB | Unifers